DE60315603T2 - Modulatoren von peroxisome proliferator-aktivierten rezeptoren - Google Patents

Modulatoren von peroxisome proliferator-aktivierten rezeptoren Download PDF

Info

Publication number
DE60315603T2
DE60315603T2 DE60315603T DE60315603T DE60315603T2 DE 60315603 T2 DE60315603 T2 DE 60315603T2 DE 60315603 T DE60315603 T DE 60315603T DE 60315603 T DE60315603 T DE 60315603T DE 60315603 T2 DE60315603 T2 DE 60315603T2
Authority
DE
Germany
Prior art keywords
methyl
phenyl
thiazol
trifluoromethylphenyl
propionic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60315603T
Other languages
German (de)
English (en)
Other versions
DE60315603D1 (de
Inventor
Scott Eugene Conner
James Allen Noblesville KNOBELSDORF
Nathan Bryan Brownsburg MANTLO
Jeffrey Michael Fishers SCHKERYANTZ
Quanrong Fishers SHEN
Alan M. Carmel WARSHAWSKY
Guoxin Noblesville ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE60315603D1 publication Critical patent/DE60315603D1/de
Application granted granted Critical
Publication of DE60315603T2 publication Critical patent/DE60315603T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Steroid Compounds (AREA)
DE60315603T 2002-02-25 2003-02-13 Modulatoren von peroxisome proliferator-aktivierten rezeptoren Expired - Fee Related DE60315603T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35980802P 2002-02-25 2002-02-25
US359808P 2002-02-25
PCT/US2003/002679 WO2003072100A1 (en) 2002-02-25 2003-02-13 Peroxisome proliferator activated receptor modulators

Publications (2)

Publication Number Publication Date
DE60315603D1 DE60315603D1 (de) 2007-09-27
DE60315603T2 true DE60315603T2 (de) 2008-05-21

Family

ID=27766138

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60315603T Expired - Fee Related DE60315603T2 (de) 2002-02-25 2003-02-13 Modulatoren von peroxisome proliferator-aktivierten rezeptoren

Country Status (8)

Country Link
US (1) US7153878B2 (https=)
EP (1) EP1480640B1 (https=)
JP (1) JP2005529077A (https=)
AT (1) ATE369855T1 (https=)
AU (1) AU2003217274A1 (https=)
DE (1) DE60315603T2 (https=)
ES (1) ES2290439T3 (https=)
WO (1) WO2003072100A1 (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072838A1 (en) * 2000-12-20 2004-04-15 Pierette Banker Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
AU2003217274A1 (en) 2002-02-25 2003-09-09 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
RU2005141516A (ru) 2003-06-06 2007-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Производные анилина
MXPA06003205A (es) * 2003-09-22 2006-06-23 Ono Pharmaceutical Co Derivados de acido fenilacetico, proceso para producir el mismo y uso.
KR100849352B1 (ko) * 2003-11-05 2008-07-29 에프. 호프만-라 로슈 아게 Ｐｐａｒ 활성화제로서 벤조-융합된 화합물
AU2004291262C1 (en) * 2003-11-05 2011-08-11 F. Hoffmann-La Roche Ag Phenyl derivatives as PPAR agonists
WO2005060958A1 (en) * 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
JP4875978B2 (ja) * 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
DE102004040736B4 (de) * 2004-08-23 2007-01-11 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Diarylcycloalkylderivaten
US20090054493A1 (en) * 2005-02-25 2009-02-26 Heonjoong Kang Kang Thiazole derivatives as ppar delta ligands and their manufacturing process
WO2006091047A1 (en) 2005-02-25 2006-08-31 Heonjoong Kang Thiazole derivatives as ppar delta ligands and their manufacturing process
ATE529404T1 (de) 2005-06-30 2011-11-15 High Point Pharmaceuticals Llc Phenoxyessigsäuren als ppar-delta-aktivatoren
SI1931660T1 (sl) * 2005-09-29 2012-12-31 Sanofi Derivati fenil-(1,2,4)-oksadiazol-5-ona s fenilno skupino, postopki za njihovo pripravo in njihova uporaba kot zdravila
BRPI0620468A2 (pt) 2005-12-22 2011-11-08 Transtech Pharma, Inc. ácidos fenóxi acéticos como ativadores de ppar delta
CN101484433A (zh) 2006-02-15 2009-07-15 艾博特公司 新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
JP2009526868A (ja) 2006-02-15 2009-07-23 アボット・ラボラトリーズ 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
WO2007101864A2 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
CN101466687B (zh) * 2006-04-18 2012-04-11 日本化学医药株式会社 过氧化物酶体增殖剂激活受体δ的激活剂
CN101595089A (zh) 2006-12-02 2009-12-02 财团法人首尔大学校产学协力财团 作为ppar配体的芳基化合物及其用途
JP5367584B2 (ja) * 2007-01-08 2013-12-11 ソウル ナショナル ユニバーシティー インダストリー ファンデーション ペルオキシソーム増殖因子活性化受容体δリガンドチアゾール化合物及びこれを含有する医薬、化粧品及び健康食品組成物
WO2008154023A1 (en) * 2007-06-11 2008-12-18 Cerenis Therapeutics S.A. Novel uses of ppar delta agonists
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
EP2540711A4 (en) * 2010-02-25 2014-01-22 Snu R&Db Foundation Selenium-Zolderivate with ligand for the activation of the peroxisome-proliferator-activated receptor (PPAR), preparation method therefor and use of the chemical compounds
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
EP2612669A4 (en) 2010-08-31 2014-05-14 Snu R&Db Foundation USING THE FÖTAL REPROGRAMMING OF A PPAR AGONIST
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US9688673B2 (en) 2011-03-08 2017-06-27 The Regents Of The University Of California Deoxycytidine kinase binding compounds
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
US20160029630A1 (en) 2012-11-27 2016-02-04 Basf Se Substituted 2-[phenoxy-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds and their use as fungicides
US20150307459A1 (en) 2012-11-27 2015-10-29 Basf Se Substituted 2-[phenoxy-phenyl]-1-[1,2,4]triazol-1-yl-ethanol Compounds and Their Use as Fungicides
WO2014082880A1 (en) 2012-11-27 2014-06-05 Basf Se Substituted [1,2,4] triazole compounds
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3116503A4 (en) * 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
AR100743A1 (es) 2014-06-06 2016-10-26 Basf Se Compuestos de [1,2,4]triazol sustituido
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (en) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetic spirochroman compounds
CN109897013B (zh) * 2019-03-31 2023-04-07 无锡科华生物科技有限公司 一种选择性PPARδ激动剂GW501516的制备方法
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
CN113912547B (zh) 2020-07-10 2024-04-30 成都凡诺西生物医药科技有限公司 取代苯丙咪唑类衍生物及其应用
WO2022094409A1 (en) 2020-11-02 2022-05-05 Trethera Corporation Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof
WO2022189856A1 (en) * 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1233241A (zh) * 1996-08-19 1999-10-27 日本烟草产业株式会社 丙酸衍生物及其用途
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
EP1310494B1 (en) * 2000-08-11 2012-01-25 Nippon Chemiphar Co., Ltd. PPAR (delta) ACTIVATORS
JP2004509084A (ja) 2000-08-23 2004-03-25 イーライ・リリー・アンド・カンパニー オキサゾリル−アリールオキシ酢酸誘導体およびそのｐｐａｒアゴニストとしての使用
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
AU2003217274A1 (en) 2002-02-25 2003-09-09 Eli Lilly And Company Peroxisome proliferator activated receptor modulators

Also Published As

Publication number Publication date
US20050107449A1 (en) 2005-05-19
EP1480640B1 (en) 2007-08-15
AU2003217274A1 (en) 2003-09-09
DE60315603D1 (de) 2007-09-27
JP2005529077A (ja) 2005-09-29
EP1480640A1 (en) 2004-12-01
US7153878B2 (en) 2006-12-26
ATE369855T1 (de) 2007-09-15
WO2003072100A1 (en) 2003-09-04
ES2290439T3 (es) 2008-02-16

Similar Documents

Publication Publication Date Title
DE60315603T2 (de) Modulatoren von peroxisome proliferator-aktivierten rezeptoren
DE69124798T2 (de) 3-aryl-2-hydroxypropionsäurederivate und analoge als hypoglykämische mittel
DE68905639T2 (de) Hypoglykaemische thiazolidindion-derivate.
DE60005973T2 (de) Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren
DE60129712T2 (de) Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
EP1480642B1 (en) Peroxisome proliferator activated receptor modulators
DE602004011985T2 (de) Modulatoren des peroxisomproliferatoraktivierten rezeptors
DE69015587T2 (de) Hypoglykämische Oxazolidindion-Derivate.
DE69109291T2 (de) Oxazolidindione als hypoglykämische und hypocholesterolämische Wirkstoffe.
DE60132799T2 (de) Peroxisom proliferator aktivierten rezeptor alpha agonisten
DE69106714T2 (de) Hypoglykämische hydroxyharnstoffderivate.
DE60216094T2 (de) Modulatoren der peroxisom-proliferator-aktivierten rezeptoren (ppar)
DE60211891T2 (de) Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes
DE60029446T2 (de) Arylthiazolidindione und aryloxazolidindion-derivate
DE69916457T2 (de) Substituierte oxazole und thiazole derivate als hppar-gamma und hppar-alpha aktivatore
DE60022207T2 (de) Benzyliden-thiazolidindione und analoga und ihre verwendung zur behandlung von diabetes
Hulin et al. Hypoglycemic activity of a series of α-alkylthio and α-alkoxy carboxylic acids related to ciglitazone
DE3871916T2 (de) Thiazolidindione als hypoglykaemische und antiatherosklerotische mittel.
DE60032898T2 (de) Arylthiazolidindion- und aryloxazolidinderivate
DE60128239T2 (de) Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
DE60210784T2 (de) Orale antidiabetische wirkstoffe
DE69836980T2 (de) Arylthiazolidindion-derivate
CZ216398A3 (cs) Sloučenina mající aktivitu agonisty PPAR-alfa a PPAR-gama, takový agonista a jeho použití, farmaceutický prostředek s jeho obsahem a způsob detekce
JP2006514069A (ja) Ｐｐａｒ調節因子としての融合複素環式誘導体
KR20050044606A (ko) 퍼옥시솜 증식제에 의해 활성화된 수용체 아고니스트

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Ref document number: 1480640

Country of ref document: EP

Effective date: 20110901

R082 Change of representative

Ref document number: 1480640

Country of ref document: EP

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN, DE